IMLYGIC® (talimogene laherparepvec) is a prescription medication injected on the skin, beneath the skin, or in your lymph glands to treat a type of skin cancer called melanoma when it can no longer be surgically removed. IMLYGIC® may not help you live longer and may not shrink canc…Read More
IMLYGIC® (talimogene laherparepvec) is a prescription …Read More
This information is intended for US healthcare professionals only.
If you are a healthcare professional, click to continue.
Continue to IMLYGIC® for professionals
Of 295 patients, 48 (16.3%) had a durable response*
with IMLYGIC® compared
to 3 out of 141 patients (2.1%) in the control group.2
Of the 48 patients who achieved a durable response with IMLYGIC®, 14 patients (29.1%) had a durable complete response. This means that all evidence of tumors disappeared for 6 months or longer.3,4
Of the 48 patients who achieved a durable response with IMLYGIC®, 34 patients (70.8%) had a durable partial response. This means the size of all tumors that could be measured was reduced by 50% or more for 6 months or longer.3,4
Of the 3 patients in the control group who achieved a durable response as described above, all of them had a durable partial response. This means that at least half of all evidence of tumors disappeared for 6 months or longer.3,4
*Unadjusted Relative Risk 7.6 (95%, CI: 2.4, 24.1), P<0.0001.
1 in 4 patients (78 out of 295, or 26.4%) saw their tumors shrink by at least half, compared with 1 in 20 (8 out of 141, or 5.7%) in the control group.2
†Overall response rate was a secondary endpoint of the study. This means that while the study was not designed to assess overall response, it was still a measurable result in the study. Overall response rate is the percentage of patients that had either a complete response or a partial response.2
Some people began to respond to treatment as early as 1.2 months, and others as late as 16.7 months.1 It is important for your doctor to monitor your condition regularly to see how your body is responding.
This time to response was another secondary endpoint of the study.2
Existing tumors may increase in size and new tumors could appear during treatment with IMLYGIC®.1
IMLYGIC® was studied in 436 patients with Stage IIIB/C and Stage IV melanoma against a control group given another treatment called Granulocyte-Macrophage Colony-Stimulating Factor, or GM-CSF.1‡
‡IMLYGIC® was injected into tumors, and the control group was given GM-CSF subcutaneously (under the skin).
How is IMLYGIC® different from other cancer medicines?
What results might I expect from IMLYGIC® treatment?
What are the potential side effects of IMLYGIC®?
Be sure to review the Important Safety Information with your doctor (see below).
Is my immune system strong enough?
People who have HIV infection or AIDS, blood or bone marrow cancer, autoimmune disease, or other medical conditions that can weaken the immune system should not take IMLYGIC®.
Download the IMLYGIC® Patient Brochure as a resource
for useful information about melanoma and IMLYGIC®.
IMPORTANT SAFETY INFORMATION
What is IMLYGIC® used for?
IMLYGIC® (talimogene laherparepvec) is a prescription medication used to treat a type of skin cancer called melanoma when it is on your skin or in your lymph glands.
IMLYGIC® may not help you live longer and may not shrink cancer in your organs (for example, lung or liver).
What is IMLYGIC® made from and how is it given?
Who should not take IMLYGIC®?
You should not get IMLYGIC® if you are pregnant or have a weakened immune system (for example, an immune deficiency, blood or bone marrow cancer, steroid use, or HIV/AIDS).
What should you tell your doctor before getting IMLYGIC®?
The IMLYGIC® virus can spread to other areas of your body or to your close contacts (household members, caregivers, sex partners, or persons sharing the same bed). Do the following to avoid spreading IMLYGIC® to other areas of your body or to your close contacts. You should share this information with them:
What are the possible side effects of IMLYGIC®?
If you would like more information, talk with your doctor.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or
call 1-800-FDA-1088.
Please see full Prescribing Information and Medication Guide for more information about IMLYGIC®.
Indication and Limitations of Use
IMLYGIC® (talimogene laherparepvec) is a prescription medication injected on the skin, beneath the skin, or in your lymph glands, to treat a type of skin cancer called melanoma when it can no longer be surgically removed.
IMLYGIC® may not help you live longer and may not shrink cancer in your organs (for example, lung or liver).
IMPORTANT SAFETY INFORMATION
Indication and Limitations of Use
What is IMLYGIC® used for? IMLYGIC® (talimogene laherparepvec) is a prescription medication used to treat a type of skin cancer called melanoma when it is on your skin or in your lymph glands. IMLYGIC® may not help you live longer and may not shrink cancer in your organs (for example, lung or liver).
References:
1. | IMLYGIC® (talimogene laherparepvec) Prescribing Information, BioVex, Inc., a subsidiary of Amgen, Inc. |
2. | Andtbacka RHI, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780-2788. |
3. | Andtbacka RHI, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(suppl Clinical Study Protocol):doi:10.1200/JCO.2014.58.3377. |
4. | Data on file, Amgen. |